LeMaitre Vascular reported strong Q4 2025 results with a 16% increase in sales and a 47% surge in operating income, driven by higher average selling prices and manufacturing efficiencies. The company also announced a 25% dividend increase and a new $100 million share repurchase program.

LeMaitre Vascular reported strong Q1 2025 results with sales up 12% organically, driven by growth in grafts and carotid shunts. The company increased its full-year sales guidance and highlighted its strategic optionality due to a strong cash position.

LeMaitre Vascular reported a productive Q4 2024 with sales up 14%, operating income up 26%, and EPS up 30%. The company also announced an increased quarterly dividend and authorized a share repurchase program.

LeMaitre Vascular reported a strong Q3 2024 with a 16% increase in sales, driven by growth in grafts, patches, and carotid shunts. The company's gross margin improved, and operating income increased significantly. Increased guidance now implies a 2024 op. margin of 24%, vs. 19% in 2023.

LeMaitre Vascular reported strong Q2 2024 results, with sales up 11% and operating income increasing by 52%. The company also announced a quarterly dividend of $0.16 per share and provided forward guidance indicating continued growth.

LeMaitre Vascular reported a strong Q1 2024 with a 14% increase in sales, driven by allografts, bovine patches, carotid shunts, and distributed porcine patches. The company's gross margin improved by 300 bps to 68.6%, and operating income increased by 51%.

LeMaitre Vascular reported a 19% increase in sales, reaching $48.9 million, and a gross margin of 68.1%, up 450 bps. Operating income grew by 46% to $10.2 million, and net income increased by 50% to $8.5 million. Earnings per diluted share rose by 49% to $0.38.

LeMaitre Vascular reported a 19% increase in sales to $50.1 million in Q2 2023, with organic growth of 16%. Operating income increased by 63% to $9.5 million, and net income rose by 130% to $8.1 million. Earnings per diluted share increased by 127% to $0.36. The company also announced a quarterly dividend of $0.14 per share.

LeMaitre Vascular reported Q1 2023 results with sales of $47.1 million, a 19% increase compared to Q1 2022. Organic growth was 22%. Operating income was $7.9 million, a 1% decrease, and net income remained flat at $6.0 million. The company announced a quarterly dividend of $0.14/share and provided Q2 and full-year guidance.

LeMaitre Vascular reported a 4% increase in sales to $41.0 million in Q4 2022, with organic sales growth of 8%. Operating income decreased by 16% to $7.0 million, while net income declined by 9% to $5.6 million. The company announced a quarterly dividend of $0.14 per share and provided Q1 2023 sales guidance of $42.6 million to $45.0 million.

LeMaitre Vascular reported a 2% increase in sales (7% organic) for Q3 2022, driven by growth in carotid shunts, Artegraft, allografts, and embolectomy catheters. Despite the sales growth and an increase in cash balance, the company experienced a decrease in operating income and net income due to increased operating expenses, including headcount and regulatory expenses.

LeMaitre Vascular reported Q2 2022 financial results with sales of $42.1 million, a 4% increase compared to Q2 2021. The company's gross margin was 66.0%. Operating income decreased by 48% to $5.8 million, while earnings per diluted share decreased by 60% to $0.16. Excluding a special charge, operating income decreased by 20% to $8.9 million, and earnings per diluted share decreased by 26% to $0.29.

LeMaitre Vascular reported a 10% increase in sales to $39.6 million in Q1 2022, with organic growth of 13%. Operating income remained flat at $7.9 million, while net income increased by 2% to $6.0 million. The company's cash and investments increased by $0.9 million to $70.9 million.

LeMaitre Vascular reported Q4 2021 financial results, with sales increasing by 5% to $39.5 million. Operating income decreased by 13% to $8.3 million, while net income decreased by 12% to $6.2 million. The company announced a quarterly dividend of $0.125/share, a 14% increase, and provided forward guidance.

LeMaitre Vascular reported Q3 2021 financial results, with sales of $38.4 million, a gross margin of 64.8%, and an operating income of $9.1 million. The company announced a quarterly dividend of $0.11 per share and provided forward guidance for Q4 2021 and full year 2021.

LeMaitre Vascular reported a strong Q2 2021 with a 64% increase in sales, reaching $40.7 million, and a 128% increase in operating income to $11.1 million. Net income increased by 137% to $8.3 million, with earnings per share at $0.40, a 131% increase. The company also announced a quarterly dividend of $0.11 per share.

LeMaitre Vascular reported strong Q1 2021 results, with a 17% increase in sales and an 83% increase in operating income. The company's bottom-line growth was driven by double-digit sales growth and restrained expenses. They also announced a quarterly dividend of $0.11/share.

LeMaitre Vascular reported Q4 2020 results with sales growth in the Americas, Asia/Pac, and Europe/Middle East/Africa. The three recent acquisitions (Artegraft, CardioCel and Eze-Sit) led growth in Q4 2020. Gross margin decreased to 65.0% due to recent acquisitions and factory transitions. Operating expenses decreased 1% due to COVID-related cost-cuts as well as reduced travel and surgeon congresses.

LeMaitre Vascular reported a 25% increase in sales to $36.4 million and a 70% increase in operating income to $10.0 million in Q3 2020. Net income increased by 45% to $7.5 million, and earnings per diluted share increased by 44% to $0.37. The company's cash and equivalents increased by $9.3 million to $34.4 million, while debt decreased by $4.5 million to $60.5 million.

LeMaitre Vascular's Q2 2020 sales decreased by 16% compared to Q2 2019, with a net income decline of 24%. However, the company maintained a solid operating margin of 20% and completed the acquisition of Artegraft.

LeMaitre Vascular reported record sales of $30.6 million, a 7% increase year-over-year, but experienced a decrease in operating income and net income. The company also announced a quarterly dividend of $0.095 per share.

LeMaitre Vascular reported record sales of $30.2 million for Q4 2019, a 6% increase compared to Q4 2018. Operating income was $4.9 million, and net income was $4.6 million. The company provided guidance for 2020, projecting 10% sales growth and 17% operating income growth.